NCT06181006

A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants

A Phase I, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LOXO-305 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to assess the safety and tolerability of pirtobrutinib and to look at the amount of the study drug, pirtobrutinib, that gets into the blood stream and how long it takes the body to get rid of it when given in healthy adult participants. For each participant, the total duration of the study will be 46 days, including screening.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Pirtobrutinib	Administered orally.

Timeline

• Start date: 2020-08-14
• Primary completion: 2020-12-01
• Completion: 2020-12-01
• First posted: 2023-12-26
• Last updated: 2025-01-14
• Results posted: 2025-01-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study